ZymoGenetics Sees Faster Approval Of Second rhThrombin Configuration
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s decision to not require Phase III study for spray version could shave 18 months off of development.You may also be interested in...
ZymoGenetics Allies With Bayer To Blitz U.S. Hospital Market With rhThrombin
ZymoGenetics Allies With Bayer To Blitz U.S. Hospital Market With rhThrombin
Johnson & Johnson/Omrix’s Evicel Approved For Use In Vascular Surgery
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: